Print Page   |   Contact Us   |   Your Cart   |   Sign In
Sign In
Sign In securely
Breaking News
News & Press: Daily Updates

FDA expands use of Pfizer's best-selling pneumonia vaccine

Wednesday, July 13, 2016   (0 Comments)

Pfizer Inc said on Tuesday the U.S. Food and Drug Administration had expanded the use of its best-selling pneumonia vaccine, Prevnar, to adults aged 18 through 49.

The vaccine, which is already approved for use in adults aged 50 and above, and children aged 6 weeks to 17 years, prevents invasive diseases caused by 13 Streptococcus pneumoniae strains.


OSAP Disclaimer | Please notify our webmaster of any problems with this website.
OSAP thanks its Super Sponsors for their support in 2017. Sponsorship does not imply endorsement by OSAP of a company's products or services.